ZIVO BIOSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.1 USD | +1.25% |
|
+1.25% | +575.00% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 61.55 | 27.03 | 23.55 | 2.423 | 22.7 | - |
| Enterprise Value (EV) 1 | 61.55 | 27.03 | 23.55 | 2.423 | 22.7 | 22.7 |
| P/E ratio | -7.5 x | -2.39 x | -2.69 x | -0.26 x | -2.93 x | -3.68 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 87.6 x | 41.7 x | 15.1 x |
| EV / Revenue | - | - | - | 87.6 x | 41.7 x | 15.1 x |
| EV / EBITDA | - | -2.99 x | -2.7 x | -0.33 x | -2.71 x | -2.94 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 855 | 1,570 | 1,570 | 2,019 | 2,803 | - |
| Reference price 2 | 72.00 | 17.22 | 15.00 | 1.200 | 8.100 | 8.100 |
| Announcement Date | 2/25/21 | 4/22/22 | 3/14/23 | 3/15/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 0.0276 | 0.545 | 1.508 |
| EBITDA 1 | - | -9.053 | -8.732 | -7.263 | -8.372 | -7.714 |
| EBIT 1 | - | -9.053 | -8.732 | -7.263 | -8.46 | -8.369 |
| Operating Margin | - | - | - | -26,267.67% | -1,552.29% | -554.97% |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income 1 | -9.106 | - | -8.745 | -7.777 | -8.472 | -8.381 |
| Net margin | - | - | - | -28,127.23% | -1,554.5% | -555.77% |
| EPS 2 | -9.600 | -7.200 | -5.580 | -4.600 | -2.760 | -2.200 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/25/21 | 4/22/22 | 3/14/23 | 3/15/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.00405 | 0.0118 | 0.0118 | 0.02 | 0.075 | 0.15 | 0.3 |
| EBITDA 1 | -3.164 | -2.027 | -2.068 | -2 | -2.638 | -1.949 | -1.801 | -1.549 | -1.897 | -2.206 | -2.08 | -2.039 | -2.047 |
| EBIT 1 | -3.164 | -2.027 | -2.068 | -2 | -2.638 | -1.97 | -1.824 | -1.572 | -1.897 | -2.228 | -2.102 | -2.061 | -2.069 |
| Operating Margin | - | - | - | - | - | - | -45,033.83% | -13,325.34% | -16,072.8% | -11,140% | -2,802.67% | -1,374% | -689.67% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | - | -2.028 | -2.072 | -2.004 | -2.641 | -1.973 | -2.071 | -1.825 | -1.909 | -2.231 | -2.105 | -2.064 | -2.072 |
| Net margin | - | - | - | - | - | - | -51,125.19% | -15,465.42% | -16,174.15% | -11,155% | -2,806.67% | -1,376% | -690.67% |
| EPS 2 | -2.040 | -1.320 | -1.320 | -1.260 | -1.680 | -1.260 | -1.320 | -1.050 | -0.9600 | -0.8000 | -0.7000 | -0.6500 | -0.6100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/22/22 | 5/13/22 | 8/4/22 | 11/14/22 | 3/14/23 | 5/10/23 | 8/14/23 | 11/13/23 | 3/15/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 2/25/21 | 4/22/22 | 3/14/23 | 3/15/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.1
USD
Average target price
12
USD
Spread / Average Target
+48.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +575.00% | 22.7M | |
| +8.20% | 7.78B | |
| +1.64% | 7.38B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M | |
| -16.45% | 802M |
- Stock Market
- Equities
- ZIVO Stock
- Financials ZIVO Bioscience, Inc.
